Policy
UK advisory body issues rapid response on psychedelic research

Published
4 months agoon

With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic research.
In May, the UK saw a parliamentary debate discussing psilocybin access, where a group of crossparty MPs called for the rescheduling of psilocybin to remove barriers to research.
The MP’s demanded an urgent review of the evidence for psilocybin’s current status as a Schedule 1 drug under the Misuse of Drugs Regulations 2001, “with a view to rescheduling”, as psychedelics are showing promise in increasing clinical research as innovative treatments for conditions such as post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD).
Ahead of the debate, The Royal College of Psychiatrists, non-profit Heroic Hearts UK – which helps provide veterans legal access to psychedelic therapies, and other leading mental health charities wrote letters to the Veterans Minister and the Minister of State for Crime, Policing and Fire, urging them to champion access for patients in the UK.
Driven by this rise in interest, the UK’s Parliamentary Office of Science and Technology (POST) has published a rapid response in a bid to elucidate the topic for policymakers. The body is one of the first of its kind in the world, sourcing independent analysis of public policy issues relating to science and tech for government.
Jo Neill, Professor of Psychopharmacology at The University of Manchester, UK, acted as an independent peer reviewer for the response, alongside Professor David Nutt, Head of Imperial College’s Centre for Psychedelic Research.
Neill told Psychedelic Health: “I was delighted to be able to peer review this thorough and well-researched policy briefing on psychedelic-assisted therapy to treat severe depression, by the Parliamentary Office of Science and Technology.
“It is very encouraging that Parliament is starting to engage with the enormous clinical potential of psychedelic medicine, particularly at a time when mental health disorders are at an all-time high.
“New therapies are urgently needed and psychedelics could provide just that. Given the weight of evidence presented in this new POST note, enabling safe patient access on the NHS must be a key priority for Parliament.”
Professor Nutt added: “I am very pleased with this report which shows how important this line of research and antidepressant clinical development is.
“I hope that both Houses of Parliament take it seriously and begin the process of rescheduling psilocybin and MDMA for treatment-resistant patients like Australia has just done.”
The response looks at how effective psychedelic medicines could be and what regulatory and legal challenges face their use, exploring topics such as “What are psychedelics?” and “How do psychedelic drugs act on the body?”.
In particular, it delves into the current research and knowledge on the substances psilocybin and ketamine, highlighting recent advances that have already been made in the UK in relation to psychedelics
These include the establishment of a partnership between the Institute for Psychiatry, Psychology and Neuroscience, South London NHS Foundation Trust and COMPASS Pathways to investigate the use of psychedelics for TRD.
POST stated in the report: “POST will publish further work on the use of psychedelic drugs for a wider range of mental health conditions, its role in elucidating other aspects of brain function, and stakeholder perspectives on their use, later in 2023. This Rapid Response focuses on their potential as a treatment for depression, given recent parliamentary interest.”
You may like
Ketamine: understanding the K-Hole
Mychedelica launches to revolutionise psychedelic medicine
Clearmind Medicine announces receipt of Nasdaq delisting notice
Paper explores extended difficulties following psychedelic trips
Transform Drugs releases groundbreaking book: How to regulate psychedelics
PAREA’s psychedelic push: improving policy for mental health innovation in Europe
Policy
Now is the time for psychedelic access, says campaigner

Published
2 weeks agoon
21st November 2023By
News Editor
Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses.
In the face of critics, Hodges has said now is the time for safe access to psychedelics.
The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.
If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.
Hodges has said: “Now is the time for safe, controlled medical access for patients in need. The way to solve the problem is not by continuing to ignore it.”
Hodges’ solution is to create a structure for use that includes proper dosages and access to experts who can help users benefit from appropriate treatment.
The updated initiative language emphasises safety, and gives doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of conditions.
Research by the University of Michigan and Columbia University shows non-LSD hallucinogenic use on the rise and Hodges has stated that increase means that the initiative providing guidelines for use is needed more than ever.
Hodges said he hopes Californians will read the initiative, share their thoughts about it over the holiday week and offer feedback via the initiative website, PW4CA.com, by 27 November, 2023, the deadline for modifications.
“Now is the time to provide medical and therapeutic access to psychedelics,” Hodges said. “The way to do this is through the initiative.”
Policy
Transform Drugs releases groundbreaking book: How to regulate psychedelics

Published
3 weeks agoon
15th November 2023
UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.
While an increasing amount of research is pointing to the potentially beneficial effects of psychedelic treatment on mental health conditions, many people across the globe are using psychedelics outside of the clinical setting.
The book includes a set of proposals for post-prohibition policies, covering psychedelics including psilocybin, LSD, DMT and Mescaline.
Previously, Transform’s guides on regulating stimulants and cannabis have been used to advise governments around the world on drug policy. This book seeks to inform the debates on psychedelic drug reforms taking place across the world.
Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Despite psychedelic drugs being illegal, their non-medical use within society has been steadily increasing.
“Punitive enforcement has not decreased use or eliminated supply, but it has made use more unsafe.
“Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and making moves to regulate for non-medical adult use.”
Scientific Chair of Drug Science, Professor David Nutt, added: “Once again Transform have come up with a well thought out and practical plan for the regulation of another group of currently illegal drugs – in this case psychedelics.
“Their ideas would be both easy to implement and to engage with and will, if adopted, radically enhance the safe use of these remarkable agents.”
Proposals for regulation
The book includes a four-tiered regulation model “that attempts to manage the variety of psychedelic preparations and the different ways in which they are used”.
These include:
- Private use, home cultivation, foraging and not-for-profit sharing.
- Membership-based non-for-profit associations for plant-based products.
- Licensed production and retail adaptable to different products and environments
- Regulated commercial guided or supervised use
Additionally, a decriminalisation model is proposed which suggests that possession for personal use should no longer be an offence of any kind or be subject to any sanctions; Drugs for personal use should not be confiscated; cultivation of small amounts of plant-based drugs for personal use should be decriminalised, among other suggestions.
The book also includes topics such as embedding social justice, equity and human rights into policy design, how to think about psychedelics regulation, why regulate psychedelics and why now, and psychedelics and the UN drug treaties.
To read the book, please visit transformdrugs.org/.
Policy
Oakland ballot seeks to legalise medical psychedelics

Published
1 month agoon
30th October 2023By
News Editor
Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.
The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.
If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.
Additionally, it would create a statewide framework for regulating the possession, use, cultivation and production of substances for medical and therapeutic use.
The initiative has been introduced by proponent and founder of the Oakland-based Church of Ambrosia, Dave Hodges, to the California Attorney General’s office for the 2024 ballot, and will need 546,651 valid signatures to qualify.
The filing follows California Governor Gavin Newsom’s recent veto of Senate Bill 58, the bill that sought to decriminalise the use of certain psychedelic drugs.
Hodges emphasised that SB58 would have been a step forward, but that it had major flaws concerning its lack of provisions to ensure access, public safety and quality control. That veto, Hodges said, compelled him to move quickly on the initiative filing.
When the California Attorney General certifies the initiative for circulation, backers will have about four and a half months to gather the required signatures for ballot placement.
Signature collecting will begin in early December.
Recent Articles
- Mapping the effects of ketamine on the brain
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
Trending
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
Trending
- Opinion2 years ago
Clerkenwell Health is launching a free UK psychedelic therapist training programme
- Insight2 years ago
Mixing psychedelics with lithium poses significant risk of seizures
- Medicinal2 years ago
MDMA therapy for PTSD granted innovation passport by UK
- Research2 years ago
LSD trial for the treatment of adult ADHD initiated
- Markets & Industry12 months ago
Where can I find training for psychedelic therapy?
- Medicinal2 years ago
MDMA: the love drug?
- News2 years ago
Awakn’s second psychedelic therapy clinic to open in London
- Research2 years ago
London to host Europe’s first commercial psychedelic clinical trial facility